

Special Issue

Novel Therapeutic Targets for the Treatment of Multiple Myeloma

Message from the Guest Editor

Multiple myeloma progression and drug resistance strongly depends on the crosstalk between tumor plasma cells and the surrounding microenvironment, highlighting the importance of target tumor plasma cells and the bone marrow microenvironment. Despite the therapeutic progress, multiple myeloma is still an incurable malignancy, and many patients undergo drug resistance or relapse. This Special Issue will focus on the recent advances in the field of multiple myeloma: novel therapeutic targets, conventional drugs, as well as innovative cell- and RNA-based therapies, with the aim of improving patient outcome and overall survival. In this Special Issue, original research articles and reviews are welcome.

Guest Editor

Dr. Ilaria Saltarella

Section of Pharmacology, Department of Precision and Regenerative Medicine and Jonian Area, School of Medicine, University of Bari Aldo Moro, 70124 Bari, Italy

Deadline for manuscript submissions

closed (31 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/152057

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)